T1	Participants 157 192	advanced colorectal cancer patients
T2	Participants 615 656	advanced colorectal cancer (ACC) patients
T3	Participants 718 780	Seven hundred and fifty five previously untreated ACC patients
T4	Participants 1116 1168	Seven hundred and thirty two patients were evaluable
